CT011 yog ib yam khoom siv GPC3 CAR T-cell uas siv los kho mob qog nqaij hlav siab (HCC). CT011 tau txais kev pom zoo IND los ntawm NMPA xyoo 2019 rau kev kho mob rau cov neeg mob uas muaj qog nqaij hlav GPC3 uas yog thawj zaug pom zoo IND hauv Suav teb rau kev kho mob CAR T-cell tiv thaiv qog nqaij hlav.
Thaum Lub Yim Hli 18, 2022, CARsgen Therapeutics tshaj tawm tias daim ntawv qhia txog rooj plaub, hu ua "Long Term Complete Response of Advanced Hepatocellular Carcinoma to Glypican-3 Specific Chimeric Antigen Receptor T-Cells plus Sorafenib, A case report", tau luam tawm hauv Frontiers in Immunology.
Cov ntaub ntawv qhia txog ib tug neeg mob Es Xias hnub nyoog 60 xyoo uas muaj tus kab mob siab B (HBV) uas tau phais mob thaum lub Tsib Hlis 2018. Thaum Lub Yim Hli 2018, qhov rov tshwm sim ntawm mob qog noj ntshav siab thiab mob ntsws metastasis tau tshwm sim tom qab phais mob, thiab tom qab ntawd nws tau txais kev kho mob transarterial chemoembolization (TACE) los kho cov kab mob siab thiab kev kho mob ntsws metastases. Ob lub hlis tom qab, nws tau nce qib thiab tau sau npe rau hauv kev sim tshuaj. Tom qab kev sau npe, tus neeg mob tau ua leukapheresis rau CAR-GPC3 T-cell manufacturing. Xya hnub tom qab leukapheresis, tus neeg mob tau pib tau txais 400 mg ntawm sorafenib ob zaug hauv ib hnub. Tus neeg mob tau txais 4 lub voj voog ntawm CAR-GPC3 T cells (CT011) kev kho mob thiab txhua lub voj voog tau muab faib ua ob lub infusions. Ua ntej txhua lub voj voog ntawm kev kho mob CT011, lymphodepletion tau ua tiav. Tag nrho ntawm 4 × 109Cov qe ntshav CAR-GPC3 T tau txhaj rau hauv cov ntshav.
Kev kho mob CT011 ntxiv rau sorafenib ua ke tau zoo heev. Tus neeg mob no tau txais cov lus teb ib nrab (PR) txij li lub hlis thib 3 thiab tau txais CR hauv lub hlis thib 12 tom qab thawj zaug ntawm CT011 infusion. Lub qog tsis muaj kev nce qib ntau tshaj 36 lub hlis thiab tswj hwm qhov xwm txheej CR ntau tshaj 24 lub hlis tom qab thawj zaug infusion.
Raws li peb paub, qhov no yog thawj zaug uas tau tshaj tawm tias muaj CR tom qab kev kho mob ua ke ntawm CAR T cell nrog tyrosine kinase inhibitors. Cov txiaj ntsig kho mob tau qhia tias kev kho mob ua ke ntawm GPC3 CAR T-cell thiab Sorafenib yuav yog txoj hauv kev tshiab rau cov neeg mob GPC3+ HCC siab heev.
Tam sim no, muaj ntau lwm yam kev sim tshuaj CAR-T hauv Suav teb, thiab lawv tab tom nrhiav cov neeg mob. Yog xav tau kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.
Xov Tooj: 4008803716
Email：myimmnet@163.com
Lub sijhawm tshaj tawm: Kaum Ib Hlis-29-2024